Your session is about to expire
← Back to Search
Pre-Surgery Chemotherapy + Trastuzumab for Breast Cancer
Study Summary
This trial is testing chemotherapy drugs and an antibody before surgery in patients with stage II-III breast cancer to see if it kills more tumor cells. Tissue samples will be collected to study how patients respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a biopsy or aspiration of my lymph nodes before starting treatment.I have or will have metallic clips in my tumor before starting treatment to help with surgery.I haven't had chemo, radiation, or major surgery for my cancer, but a sentinel lymph node biopsy is okay.My breast cancer is confirmed and I plan to have surgery after initial treatment.My doctor agrees I can undergo chemotherapy and surgery before my main treatment.I am willing to sign consent and provide blood samples, and I'm open to optional research biopsies.The hormone status of my cancer was tested before starting treatment.I've had a mammogram in the last 6 months and possibly an ultrasound or MRI if needed.I have stopped taking tamoxifen or similar medications at least a week ago.
- Group 1: Stratum C (AC followed by paclitaxel)
- Group 2: Stratum B (paclitaxel followed by AC)
- Group 3: Stratum A (HER2-positive disease)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the cap on participants for this medical trial?
"This medical trial is currently not open to participants. It was originally published on June 1st, 2013 and the most recent edit occurred August 11th 2022. If you are looking for other studies, 2293 trials recruiting patients with stage iia breast cancer and 1825 clinical tests searching for Paclitaxel volunteers are available."
Is this experiment pioneering a new avenue of research?
"Globally, 1825 trials investigating Paclitaxel are in progress across 3709 cities and 82 nations. This therapeutic agent was originally tested by Alfacell back in 1997 when 300 participants were enrolled for a Phase 3 evaluation. Since then, 3138 assessments have been finished."
Has Paclitaxel been the focus of any previous medical investigations?
"Currently, 1825 studies are being conducted that research Paclitaxel of which 410 have entered Phase 3. Though the majority of these trials occur in Seattle, Washington, there are almost 78 thousand locations involved worldwide."
Is enrollment still open for this medical investigation?
"As per data hosted on clinicaltrials.gov, this particular research project is not presently recruiting patients. The trial was first posted in June 2013 and last updated in August 2022; however, there are over four thousand additional trials actively enrolling participants."
Share this study with friends
Copy Link
Messenger